PPP1R26-AS1: A Potential Drug Target and Biomarker (G100506599)

Target Name: PPP1R26-AS1

NCBI ID: G100506599

PPP1R26-AS1

Other Name(s): RP11-426A6.7 | PPP1R26 antisense RNA 1

PPP1R26-AS1: A Potential Drug Target and Biomarker

PPP1R26-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the homeostasis of the body and has been implicated in a number of diseases, including neurodegenerative disorders, diabetes, and cardiomyopathy.

The protein PPP1R26-AS1 is a member of the PPP1R family, which includes several related proteins that play important roles in the regulation of protein synthesis and degradation. The PPP1R26-AS1 protein is characterized by a unique N-terminus that consists of a 26 amino acid residue and a C-terminus that is rich in acidic amino acids, as well as a R26 side chain.

Expression and Localization

PPP1R26-AS1 is expressed in a variety of tissues and organs, including the brain, where it is widely distributed and has been shown to be involved in the development and progression of neurodegenerative disorders. It is also expressed in the heart and kidneys, where it is involved in the regulation of ion and water homeostasis.

PPP1R26-AS1 is primarily localized to the cytoplasm of cells, where it can be detected using techniques such as immunofluorescence microscopy and biochemical assays. It is also shown to be present in the endoplasmic reticulum (ER), which is a system of organelles that transports and modifies proteins before they are released into the cytoplasm.

Function and Interaction

The function of PPP1R26-AS1 is not well understood, but it is believed to play a role in the regulation of protein synthesis and degradation. It is involved in the negative regulation of protein synthesis by the translation factor eIF2F1, which is critical for the initiation of protein synthesis.

PPP1R26-AS1 is also involved in the regulation of protein degradation, which is important for maintaining the homeostasis of cells. It is shown to interact with the protein known as TIR1, which is involved in the regulation of intracellular signaling pathways. This interaction between PPP1R26-AS1 and TIR1 suggests that they may work together to regulate the balance between protein synthesis and degradation.

Drug Targeting

The potential drug targets for PPP1R26-AS1 are numerous and varied. One of the main targets is the regulation of neurodegenerative disorders, which are characterized by the progressive loss of neurons and other cells in the nervous system.

PPP1R26-AS1 has been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is also involved in the regulation of the development and progression of neurodegenerative disorders in animal models, such as the role of PPP1R26-AS1 in the development of neuro-inflammation in the brain.

Another potential drug target for PPP1R26-AS1 is the regulation of diabetes, which is a metabolic disorder that is characterized by the absence of insulin in the body. PPP1R26-AS1 is involved in the regulation of insulin sensitivity and has been shown to play a role in the development of insulin resistance.

In addition, PPP1R26-AS1 is also involved in the regulation of cardiomyopathy, which is a condition characterized by the thickening of the heart muscle and can lead to heart failure. It is thought to

Protein Name: PPP1R26 Antisense RNA 1

The "PPP1R26-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R26-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets